In T2D inadequately controlled with metformin, orforglipron reduced HbA(1c) more than dapagliflozin at 40 wk.

In adults with T2D inadequately controlled on metformin, orforglipron lowered HbA1c more than dapagliflozin at 40 weeks.

• Why it matters: People whose T2D remains inadequately controlled on metformin need additional options that improve glycemic control.
• What they did: In a comparative trial in this metformin-inadequately-controlled T2D population, HbA1c changes were assessed at 40 weeks between orforglipron and dapagliflozin.
• The result: The greater HbA1c reduction with orforglipron at 40 weeks suggests it may provide stronger glycemic improvement than dapagliflozin in this specific patient group.

AI summary of the abstract · may contain errors · not medical advice · read the paper.